In the context of HER2-positive breast cancer, the receptor tyrosine kinase EphA2 has been found to promote glutamine metabolism by activating the transcriptional coactivators YAP and TAZ, suggesting potential therapeutic targets in this cancer subtype [108]. The gene discussed is EPHA2; the disease is breast carcinoma.